[{"orgOrder":0,"company":"Abliva","sponsor":"Pharming","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"KL1333","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Abliva","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Abliva \/ Pharming","highestDevelopmentStatusID":"8","companyTruncated":"Abliva \/ Pharming"},{"orgOrder":0,"company":"Abliva","sponsor":"Owl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"OWL-1410","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abliva \/ Owl Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Abliva \/ Owl Therapeutics"},{"orgOrder":0,"company":"Abliva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KL1333","moa":"NAD","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abliva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Abliva \/ Inapplicable"},{"orgOrder":0,"company":"Abliva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KL1333","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Abliva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abliva \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Abliva

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The proposed acquisition will strengthen Pharming’s late-stage pipeline disease asset. Abliva’s lead product, KL1333, is being evaluated for mitochondrial diseases.

                          Product Name : KL1333

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 15, 2024

                          Lead Product(s) : KL1333

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Pharming

                          Deal Size : $66.1 million

                          Deal Type : Acquisition

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Abliva lead product candidate KL1333 is being evaluated in the mid-stage clinical trial studies with patients for the treatment of Primary Mitochondrial Disease.

                          Product Name : KL1333

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 18, 2024

                          Lead Product(s) : KL1333

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the collaboration, Owl Therapeutics will advance Abliva's clinical development of NeuroSTAT (OWL-1410) with orphan drug designation, which is under development for the prevention and treatment of moderate to severe traumatic brain injury (TBI).

                          Product Name : NeuroSTAT

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          November 17, 2023

                          Lead Product(s) : OWL-1410

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : IND Enabling

                          Sponsor : Owl Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : KL1333 is a potent modulator of the cellular levels of NAD, a central co-enzyme in the cell’s energy metabolism. The clinical KL1333 development plan will target patients with genetically confirmed MIDD-MELAS or KSS-CPEO spectrum disorders with multi-o...

                          Product Name : KL1333

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 07, 2020

                          Lead Product(s) : KL1333

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank